Onofre, Aurora Pujol, M.D. Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2011
NCT01495260
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Onofre, Aurora Pujol, M.D.

Active Ingredients

Drugs in Phase 3 Trials (1)

albumin (Human) (Plasbumin) (1 trial)

Drugs in Phase 2 Trials (4)

acetylcysteine (mucomyst) (1 trial)

alpha-lipoic acid (1 trial)

pioglitazone (actos) (1 trial)

vitamin e (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adrenoleukodystrophy (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 5